We have taken the decision to move the committee discussion for this appraisal to the meeting of the Highly Specialised Technologies Evaluation Committee on 14 February 2024. Please note that this topic will still be considered as a Single Technology Appraisal.
This decision was taken to allow both this appraisal and the appraisal of exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015] – the same therapy in a different indication – to be considered by the same committee.